EP321: How to Point Out Low-Value Care Without Starting a Fistfight, With Rich Klasco, MD
May 06, 2021
321
29:44

EP321: How to Point Out Low-Value Care Without Starting a Fistfight, With Rich Klasco, MD

If you listen to this show on the regular, you probably have a pretty good bead on a couple of things I’ve been really into lately. One of them is high-value care versus low-value care. These are terms that are really easy to throw around. You also can get pretty much everybody to agree with a plan to deliver only high-value care and quit it with the low-value care … in theory. But the wheels fall right off the bus when it comes to actually doing this.

IRL (in real life), what constitutes high-value care and what is low-value care exactly and specifically? This answer is the crucible for value-based care of almost any flavor. How are you supposed to do value-based care successfully when it remains an open question, “What is care that is of value?”

Here’s the good news, though. There is a bounty of unmistakably, inarguably low-value things. We can start there. Now, these low-value things may be situational in some respects, so you’ll need to listen to my interview with Dr. Mark Fendrick (EP308) for the scoop on that nuance. But there are definitely some things which are incontrovertibly low value.

Here’s some more good news. There’s a few ways to ferret out low-value things, and one of them is to look at data on practice patterns across a specialty. You can index the data nationally or regionally or even within the same practice. Here’s an example: Let’s just say, on average, a dermatologist does 1.74 cuts or surgical slices for Mohs surgery, where they often get paid by the cut, by the way. However, you can find some physicians who are outliers—derms who have two standard deviations above that average. The good news is that a lot of the times, all you have to do is show the doctors the data. Show them that they’re an outlier and they’ll alter their practice patterns.

So, one way to figure out what the standard of care should be is by looking at physicians’ actual experience and practices. That seems very fair. Marty Makary, Will Bruhn, and others from the team at Hopkins get a lot of credit for their pioneering work in this area. Other ways include assessing pubs and the guidelines that societies put out. I’m also sure that, more and more, it will also involve combing through real-world evidence.

In this health care podcast, I speak with Rich Klasco, MD, who is chief medical officer at Motive Medical Intelligence; and we talk about the challenges and opportunities and solutions when it comes to identifying high- versus low-value care. Dr. Klasco has an interesting construct for this. We also talk about how patients, providers, and payers might have different points of view, incentives, and capacities really to distinguish the high from the low.

You can learn more at motivemi.com. For more information and the case study, please visit motivepw.com/resources.  

Rich Klasco, MD, FACEP, has focused throughout his career on rendering evidence-based medicine operational—that is, making the right thing the easy thing to do. He has pursued this goal in academia, in industry, in policy, and in the press.

In addition to publishing extensively in both peer-reviewed journals such as JAMA and lay publications such as The New York Times, Dr. Klasco has taught at leading academic medical centers, including Harvard, Stanford, Mayo, and the University of California, San Francisco; served on the executive committee of Brigham and Women’s Hospital Center for Patient Safety Research and Practice; testified before the United States Congress on evidence-based practices; and won CMS approval for an officially designated compendium of evidence-based oncologic drug information. Dr. Klasco previously served as chief medical officer and editor-in-chief for the Thomson Reuters group of health care companies, where he had editorial responsibility for companies including Micromedex, the Physicians’ Desk Reference (PDR), and the United States Pharmacopoeia (USP) Drug Information.

For the past 15 years, Dr. Klasco has served as chief medical officer for Motive Medical Intelligence, where he provides clinical leadership for the development and deployment of solutions that quantitative assess physician performance for payers, providers, and patients, and integrate scientific knowledge into workflow systems where it can be accessed and applied in real-time.

Dr. Klasco received his medical degree from Harvard Medical School. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital, and he completed his residency in emergency medicine at the Denver Health Residency in Emergency Medicine, where he served as chief resident.


03:31 How do you define high-value care?
04:40 How do we define what isn’t appropriate care?
05:26 Why aren’t patients good at recognizing high-value care?
07:02 “He was in the ‘more is more’ school of medicine, which is always wrong.”
11:54 Are payers good at identifying high-value care?
13:41 Why are payers so adept at understanding what high-value care really is?
15:53 “It’s not just cost cutting; it’s utilization, optimization of resources.”
16:02 “This is, again, an innovation of appropriateness.”
18:38 “We have to deal with the world that we have in front of us now.”
19:55 How do we get everyone on the same page about high-value and appropriate care?
24:16 How does a team recognize the path forward for appropriate care?

You can learn more at motivemi.com. For more information and the case study, please visit motivepw.com/resources.

healthcare,pharma,value-based care,vbc,digital health,motive medical intelligence,appropriate care,
|
|

Episode Support Provided By

Special Thanks to Our 2026 Sustaining Monthly Donors

Marilyn Bartlett, Kimberly Carleson, Dylan Yahn, Benjamin Light, Matt McQuide, Ann Kempski, Spencer Allen, Scott Tromanhauser, 
Steven Elkins, Matthew Bunte, and Lori Smith.

Recent Episodes

EP533: Level Funding Is Self-funding: 5 Avoidable Contract Risks, With Frank Pennachio
Relentless Health ValueOctober 14, 2026
533
37:1334.07 MB

EP533: Level Funding Is Self-funding: 5 Avoidable Contract Risks, With Frank Pennachio

Hello, all you Relentless Tribe members. Thanks for hanging with me today to talk about a bunch of things. One of them being what exactly are level-funded plans, and what are the upsides, and then what are the risks? Because here's the thing. I was talking to an employer the other day, an employer w...

EP532: Why Avoidable ER Visits Aren't the Real Cost Problem: Revisiting Our 2016 Interview With HHS Nominee Chris Klomp
Relentless Health ValueOctober 07, 2026
532
37:2034.17 MB

EP532: Why Avoidable ER Visits Aren't the Real Cost Problem: Revisiting Our 2016 Interview With HHS Nominee Chris Klomp

Listen on Your Favorite App Today we are dipping into the archives for an essential replay from 2016, one decade ago, featuring Chris Klomp back when he served as CEO of a company called Collective Medical. With the nomination of Chris Klomp to serve as deputy secretary of the Department of Health a...

EP531: Slaying the Three-Headed Monster of Health Plan Networks, With Evan Anderson
Relentless Health ValueSeptember 30, 2026
531
38:0634.88 MB

EP531: Slaying the Three-Headed Monster of Health Plan Networks, With Evan Anderson

Listen on Your Favorite App Today, Evan Anderson and I are talking about carrier networks, how they started, how it's going. Because irrespective of whatever the plan was at the very beginning, any given network, especially talking about the big status quo networks, has evolved into what I'll call a...

EP530: A Wildly Underappreciated Point: Overpaying for Infusions Means Overpaying for Stop-Loss Coverage, With Jake Velie and Keith Hartman, RPh
Relentless Health ValueSeptember 23, 2026
530
37:4534.56 MB

EP530: A Wildly Underappreciated Point: Overpaying for Infusions Means Overpaying for Stop-Loss Coverage, With Jake Velie and Keith Hartman, RPh

Listen on Your Favorite App Hello, all you Relentless Tribe members. Thanks for hanging with me this week. When a self-insured plan sponsor sees an infusion claim hit their high-cost case report, and a lot of these infusions are really expensive, so many of them hit the high-cost claim report. For a...

EP529: How Stark Law, Stipends, and Noncompetes Drive Hospital Consolidation, With Eric Bricker, MD
Relentless Health ValueSeptember 16, 2026
529
39:2936.14 MB

EP529: How Stark Law, Stipends, and Noncompetes Drive Hospital Consolidation, With Eric Bricker, MD

Listen on Your Favorite App Hello, all you Relentless Tribe members. Hey, thanks for being here with me every week, some of you every single Thursday. Give yourself a little round of applause, maybe silently and in your own head, depending on where you are. But yeah, you matter. You being here matte...

EP528: The Current State of Primary Care—Inevitable or Fixable? Will It Be Private Equity to the Rescue? With Yashaswini Singh, PhD
Relentless Health ValueSeptember 09, 2026
528
38:4935.53 MB

EP528: The Current State of Primary Care—Inevitable or Fixable? Will It Be Private Equity to the Rescue? With Yashaswini Singh, PhD

Listen on Your Favorite App Hello, all you Relentless Tribe members. Here's the backstory for this episode. Remember episode 519 with Lisa Rosenbaum, MD, where we played a high-stakes kind of game show called "Is the Current State of Primary Care an Absolute Inevitability, or Is It a Needless, Subop...

EP526: Generic Compliance Ratios, Pass-Through Contracts, and Other Pharmacy Plumbing, With Mark Cuban and Cora Opsahl
Relentless Health ValueAugust 26, 2026
526
20:1119.06 MB

EP526: Generic Compliance Ratios, Pass-Through Contracts, and Other Pharmacy Plumbing, With Mark Cuban and Cora Opsahl

Listen on Your Favorite App Hello, all you Relentless Tribe members. If you have listened to this show for any length of time, you know one of our favorite truths around here, which is where there's mystery, there's margin. But today, we aren't just here to point out the mystery. We're here to look ...

Listen and Follow

Sponsored by Aventria Health Group
©2026 BD Bridges LLC. All Rights Reserved.